22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for biotechs...
21:31 , Feb 16, 2018 |  BioCentury  |  Finance

Listing single

Chinese cancer company 3D Medicines Corp. is vying for a Hong Kong or NASDAQ listing this year and is restructuring as a Cayman Islands-based entity in order to tap public funds while keeping its diagnostics...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Financial News

3DMed raises RMB670M

Cancer company 3D Medicines Corp. (Shanghai, China) raised RMB670 million ($101.1 million) on Nov. 23 in a round led by China Reform Holdings Corp. Ltd. ChinaEquity Group and undisclosed other investors also participated. 3DMed and Suzhou...
23:07 , Nov 28, 2017 |  BC Extra  |  Financial News

3DMed raises RMB670M

Cancer company 3D Medicines Corp. (Shanghai, China) raised RMB670 million ($101.5 million) in a round led by China Reform Holdings Corp. Ltd. ChinaEquity Group and undisclosed other investors also participated. 3DMed and Suzhou Alphamab Co....
21:45 , Sep 21, 2017 |  BC Innovations  |  Translation in Brief

Alphamab's soup

Chinese protein engineering company Alphamab is building a one-stop antibody production facility housing a slew of multispecific antibody-generating technologies and its own GMP plant under construction. The company has its own spin on the well-trodden...
21:51 , Dec 2, 2016 |  BC Week In Review  |  Clinical News

KN035: Ph I start

The partners said they plan to begin a clinical trial "shortly" after FDA approved an IND for KN035. The open-label, U.S. Phase I trial will evaluate 1, 2.5, 5 and 10 mg/kg subcutaneous KN035 given...
00:32 , Dec 2, 2016 |  BC Extra  |  Clinical News

FDA clears IND for injectable anti-PD-L1

3DMed (Shanghai, China) and Suzhou Alphamab Co. Ltd. (Suzhou, China) said FDA cleared an IND for KN035, a subcutaneous anti-PD-L1 single domain antibody fused to an Fc. The companies partnered earlier this year to develop KN035...
07:00 , Mar 14, 2016 |  BC Week In Review  |  Company News

Alphamab, 3DMed deal

3DMed and Alphamab partnered to develop and commercialize Alphamab’s KN035 to treat cancer, focusing on immunity against tumors. Both companies will be responsible for development, commercialization and production. The companies expect to begin Chinese clinical...